Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds

Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). The Company's antibody therapy, RZ358, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital hyperinsulinism (cHI) and tumor hyperinsulinism (tHI). | --- | |---------------------------------------| | | | Contacts: | | Rezolute, Inc. | | Christen Baglaneas | | cbaglanea ...